top of page
Mablink builds its pipeline on the topoisomerase-I inhibitor exatecan as a payload for current developments
Our pipeline strategy
The PSARLink™ platform being especially suited for the use of moderately potent ADC payloads, Mablink builds its pipeline on the topoisomerase-I (topo-I) inhibitor exatecan as a payload, for current developments.
The topo-I inhibitor family (including irinotecan and topotecan) is active against a wide range of tumors (including breast, colorectal and ovarian cancer) and is better tolerated than tubulin inhibitors and DNA alkylators, hence a broader therapeutic window (confirmed clinically by Enhertu®).
Mablink focuses its development on worst prognosis indications.
Acute myeloid leukemia (AML)
FIH in 2024
Non-Hodgkin's lymphoma (NHL)
bottom of page